NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
13/01/2026
Voltar para busca
Dado oficial do USPTO
FORMA THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
FORMA THERAPEUTICS
ST13
US500000087944961Classe
1, 5, 42, 44
Pedido
87944961
Registro
5689302
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
03/02/2026
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
01/06/2018
Data de registro
05/03/2019
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/01/2026
Última transação
03/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
704
Cadastro oficial
Principal Register
Primeiro uso
01/12/2008
Primeiro uso no comércio
01/12/2008
Código do desenho
4
Tipo de titular
03
Localização do titular
Watertown, MA
Examinador
STOIDES, KATHERINE
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Forma Therapeutics, Inc.
Representantes
Edward T. White Williams Mullen Center
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
chemical compounds for use in bio-pharmaceutical research
Classe 5
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation; pharmaceutical preparations for the treatment of immune-mediated conditions; pharmaceutical preparations for the treatment of neuro-degenerative diseases
Classe 42
research and development of pharmaceuticals for others ; research and development of pharmaceuticals for the treatment of cancer; research and development of pharmaceuticals for the treatment of inflammations; research and development of pharmaceuticals for the treatment of immune-mediated conditions; research and development of pharmaceuticals for the treatment of neuro-degenerative diseases; scientific and medical research in the fields of oncologyimmunology and immune-oncologyinflammationimmune-mediated diseasesprotein homeostasisepigenetics and protein metabolism
Classe 44
Providing a web site featuring information relating to the biology of potential medical treatment such as protein homeostasisepigeneticsprotein metabolism and/or immunology
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
8.PR
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
13/01/2026
PRAN
POST REGISTRATION ACTION MAILED NO RESPONSE REQUIRED
13/01/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
13/01/2026
ES8R
TEAS SECTION 8 RECEIVED
04/09/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
05/03/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/09/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/09/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/09/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/09/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/09/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
14/04/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/04/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/04/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/04/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
14/04/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
05/03/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/12/2018
PUBO
PUBLISHED FOR OPPOSITION
18/12/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/11/2018
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/11/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/11/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/11/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/11/2018
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
05/11/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/10/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/10/2018
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
09/10/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/10/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/10/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/09/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
21/09/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
21/09/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
21/09/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
21/09/2018
CEPE
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
21/09/2018
ALIE
ASSIGNED TO LIE
21/09/2018
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
21/09/2018
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
21/09/2018
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
21/09/2018
DOCK
ASSIGNED TO EXAMINER
20/09/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/06/2018
NWAP
NEW APPLICATION ENTERED
05/06/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace FORMA THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.